Eric E. Swayze's most recent trade in Ionis Pharmaceuticals Inc was a trade of 10,000 Common Stock done at an average price of $49.2 . Disclosure was reported to the exchange on Sept. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 49.22 per share. | 02 Sep 2025 | 10,000 | 38,432 (0%) | 0% | 49.2 | 492,200 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 53.68 per share. | 02 Sep 2025 | 1,130 | 37,302 (0%) | 0% | 53.7 | 60,662 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Other type of transaction at price $ 28.21 per share. | 28 Feb 2025 | 415 | 48,432 (0%) | 0% | 28.2 | 11,708 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 3,714 | 49,384 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 32.31 per share. | 30 Jan 2025 | 1,367 | 48,017 (0%) | 0% | 32.3 | 44,162 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 33,000 | 79,728 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 22,000 | 64,482 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 19,111 | 52,824 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 19,111 | 60,617 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 32.84 per share. | 15 Jan 2025 | 7,154 | 45,670 (0%) | 0% | 32.8 | 234,959 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 245 | 671 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 49 | 622 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 49 | 206 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 32.68 per share. | 15 Jan 2025 | 22 | 184 (0%) | 0% | 32.7 | 719 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 22,000 | 22,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 163 | 163 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 37.92 per share. | 12 Nov 2024 | 1,194 | 33,713 (0%) | 0% | 37.9 | 45,278 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2024 | 125 | 210 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2024 | 125 | 426 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 38.32 per share. | 15 Oct 2024 | 53 | 157 (0%) | 0% | 38.3 | 2,031 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Other type of transaction at price $ 38.64 per share. | 30 Aug 2024 | 11 | 34,907 (0%) | 0% | 38.6 | 425 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | Officer Level 14 | Other type of transaction at price $ 34.42 per share. | 29 Feb 2024 | 605 | 34,929 (0%) | 0% | 34.4 | 20,827 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 49.56 per share. | 02 Feb 2024 | 1,940 | 34,291 (0%) | 0% | 49.6 | 96,149 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 52.00 per share. | 31 Jan 2024 | 10,773 | 32,516 (0%) | 0% | 52 | 560,196 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 3,715 | 36,231 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Swayze E. Eric | EVP Research | Sale of securities on an exchange or to another person at price $ 49.56 per share. | 31 Jan 2024 | 1,907 | 34,324 (0%) | 0% | 49.6 | 94,513 | Common Stock |
| Ionis Pharmaceuticals Inc | E. Swayze Eric | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 17,069 | 46,728 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Swayze Eric E. | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 17,069 | 49,585 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Swayze Eric E. | EVP Research | Sale of securities on an exchange or to another person at price $ 50.42 per share. | 16 Jan 2024 | 6,296 | 43,289 (0%) | 0% | 50.4 | 317,425 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 21 | 551 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Swayze Eric E. | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 21 | 94 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | E. Eric Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 50.44 per share. | 16 Jan 2024 | 9 | 85 (0%) | 0% | 50.4 | 454 | Common Stock |
| Ionis Pharmaceuticals Inc | E. Swayze Eric | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 20,400 | 63,797 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | E. Swayze Eric | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 17,000 | 42,482 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Swayze E. Eric | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 116 | 572 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Swayze Eric E. | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 27,200 | 27,200 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | E. Eric Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 154 | 154 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Eric Swayze E. | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 28 Dec 2023 | 27,100 | 59,616 (0%) | 0% | 47.3 | 1,282,914 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric Swayze E. | EVP Research | Sale of securities on an exchange or to another person at price $ 50.19 per share. | 28 Dec 2023 | 27,100 | 32,516 (0%) | 0% | 50.2 | 1,360,081 | Common Stock |
| Ionis Pharmaceuticals Inc | E. Eric Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Dec 2023 | 27,100 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Other type of transaction at price $ 30.51 per share. | 28 Feb 2023 | 575 | 32,516 (0%) | 0% | 30.5 | 17,546 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 3,715 | 33,756 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 40.79 per share. | 03 Feb 2023 | 1,815 | 31,941 (0%) | 0% | 40.8 | 74,031 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 15,780 | 43,397 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 15,780 | 35,672 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 39.74 per share. | 17 Jan 2023 | 5,631 | 30,041 (0%) | 0% | 39.7 | 223,800 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 17,207 | 59,177 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 14,338 | 25,482 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 81 | 581 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 22,942 | 22,942 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 108 | 108 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2022 | 500 | 500 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2022 | 1,000 | 1,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 44.55 per share. | 08 Sep 2022 | 460 | 19,892 (0%) | 0% | 44.6 | 20,493 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 05 Aug 2022 | 1 | 20,352 (0%) | 0% | 45 | 45 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Sale of securities on an exchange or to another person at price $ 44.15 per share. | 21 Apr 2022 | 378 | 20,353 (0%) | 0% | 44.2 | 16,689 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Other type of transaction at price $ 28.37 per share. | 28 Feb 2022 | 621 | 20,731 (0%) | 0% | 28.4 | 17,620 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 13,809 | 25,104 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 13,809 | 41,970 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.12 per share. | 18 Jan 2022 | 4,994 | 20,110 (0%) | 0% | 30.1 | 150,419 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 14,859 | 55,779 | - | - | Restricted Stock Unit | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 11,144 | 11,144 | - | - | Performance Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Eric E. Swayze | EVP Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 29,718 | 29,718 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Eric Swayze | EVP, Research | Other type of transaction at price $ 44.54 per share. | 26 Feb 2021 | 460 | 11,295 (0%) | 0% | 44.5 | 20,488 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric Swayze | EVP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 23,976 | 23,976 | - | - | Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Eric Swayze | EVP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 8,944 | 14,051 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharmaceuticals Inc | Eric Swayze | EVP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 8,944 | 16,944 | - | - | Restricted Stock Units | |
| Ionis Pharmaceuticals Inc | Eric Swayze | EVP, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.28 per share. | 15 Jan 2021 | 3,216 | 10,835 (0%) | 0% | 61.3 | 197,076 | Common Stock |
| Ionis Pharmaceuticals Inc | Eric Swayze | EVP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 53,945 | 53,945 | - | - | Employee Stock Option (right to buy) | |
| Ionis Pharmaceuticals Inc | Eric Swayze | EVP, Research | Sale of securities on an exchange or to another person at price $ 55.99 per share. | 04 Jan 2021 | 195 | 5,107 (0%) | 0% | 56.0 | 10,918 | Common Stock |